Calidi Biotherapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $45,000 | — |
| Operating income | -$20.2M | -$21.8M | -$29.0M | -$23.1M | — |
| Operating expenses | $20.2M | $21.8M | $29.0M | $23.2M | — |
| Cash from operations | -$21.3M | -$19.7M | -$27.0M | -$13.2M | — |
| Total assets | $8.9M | $14.2M | $10.0M | $2.6M | $231.8M |
| Total liabilities | $5.1M | $12.2M | $18.3M | $43.4M | $16.5M |
| Total debt | $690,000 | $3.8M | $2.9M | $5.4M | — |
Shares outstanding 19.3M · Free float 20.4%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.